Douglas B. Snyder serves as Chief Legal Officer at IDEAYA Biosciences, Inc., a precision oncology company developing targeted therapies for cancer patients. With over 25 years of experience in the life sciences industry, Snyder oversees all legal matters for the company, including intellectual property strategy, corporate governance, regulatory compliance, strategic partnerships, and mergers and acquisitions. His leadership ensures IDEAYA's innovative pipeline, featuring IDE397 and other synthetic lethality programs, advances efficiently through clinical development while mitigating legal risks in a highly regulated sector. Snyder's distinguished career includes serving as Senior Vice President and Chief Legal Officer at Kite Pharma, a leader in cell therapy, from 2015 to 2020, where he guided the company through its $12 billion acquisition by Gilead Sciences and supported the FDA approval of Yescarta®, the first CAR-T therapy. Prior to Kite, he spent 13 years at Amgen Inc. in progressively senior legal roles, culminating as Executive Director and Head of Litigation, managing high-stakes patent disputes, commercial litigation, and global compliance programs. Earlier, Snyder was a partner at Latham & Watkins LLP, specializing in life sciences transactions and litigation. A graduate of the University of California, Berkeley (B.A.) and UCLA School of Law (J.D.), Snyder is recognized for his strategic acumen in navigating complex biotech landscapes. His achievements include securing key intellectual property protections and facilitating blockbuster deals that have propelled therapeutic innovations to market, positioning IDEAYA for sustained growth in precision medicine.